Global PLK Targeted Therapies Market Opportunity & Clinical Trials Insight 2024
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
Global PLK Targeted Therapies Market Opportunity & Clinical Trials Insight 2024 Report Highlights:
PLKs regulate several stages of the cell cycle, including mitosis, centrosome maturation, spindle assembly, chromosomal segregation, and cytokinesis. They also take part in DNA damage response and checkpoint control systems. Overexpression and dysregulation of PLKs have been observed in various types of cancer, contributing to uncontrolled cell proliferation, genomic instability, and resistance to chemotherapy and radiation therapy. Inhibition of PLKs can induce mitotic catastrophe, leading to cell cycle arrest and apoptosis in cancer cells.
Emerging evidence also suggests that PLKs may be involved in the regulating of immune cell function and inflammation, making them potential targets for autoimmune diseases such as lupus, rheumatoid arthritis, and multiple sclerosis. Further, some viruses, like human immunodeficiency virus (HIV) and hepatitis B virus (HBV), hijack host PLKs for their replication and pathogenesis, suggesting that PLK targeted therapies m ay have antiviral effects by dampening these processes.
As a result of these growing investigations, various small molecule inhibitors of PLKs have been found and are being developed, with some currently in clinical trials. Onvansertib, a PLK1 inhibitor developed by Cardiff Oncology, is currently the most advanced candidate in clinical trials. Onvansertib is being studied in a phase 2 trial to determine its safety and efficacy in patients with small cell lung cancer (SCLC) who have not responded to or are unable to tolerate chemotherapy. Aside from being researched in several solid malignancies, Onvansertib is currently undergoing a phase 1 trial to determine its efficacy and safety in the treatment of patients with recurrent or refractory chronic myelomonocytic leukemia.
Other candidates in the pipeline include RP-1664 and BAL0891, which are being assessed in solid cancers and CFI-400945, being studied for various hematological cancers. The progression of these candidates through the pipeline reflects the growing interest and confidence in PLK targeted therapies.
In addition to small molecule inhibitors, antisense oligonucleotides and PROTACs (proteolysis-targeting chimeras) are being investigated as potential PLK targets. Antisense oligonucleotides can selectively reduce PLK mRNA expression, whereas PROTACs cause proteasomal breakdown of PLK proteins, providing alternative methods to conventional kinase inhibitors. While these methods have shown promise in research and preclinical trials, their clinical implementation has proven difficult for a variety of reasons. However, ongoing research seeks to create more selective and powerful alternatives with better safety profiles.
As interest in PLK targeted therapies grows, pharmaceutical companies will have an opportunity to create and commercialize innovative PLK inhibitors or other PLK-targeting modalities. PLK inhibitors, degraders, and silencers have the potential to meet unmet medical needs in cancer, autoimmune disorders, and viral diseases, making them a valuable market opportunity. Established pharmaceutical corporations may seek alliances and partnerships with academic institutions or biotech companies to work on PLK targeted therapies, leveraging their experience and accelerating the development of novel treatments.
Looking ahead, the future of PLK targeted therapies in the pharmaceutical sector is promising. Continued research efforts, novel drug discovery techniques, and clinical advances will propel the development of next-generation PLK targeted therapies with enhanced efficacy and safety profiles. PLK inhibitors may be used in combination with other anticancer treatments to improve therapeutic efficacy and overcome resistance mechanisms. Furthermore, as our understanding of the genetic and molecular profiles of various cancers and disorders grows, PLK-targeted therapies may be customized to specific patient populations using biomarkers or genetic fingerprints.
In conclusion, PLK targeted therapies are a rapidly developing field with revolutionary promise across a wide range of disease areas. While significant progress has been made in the development of small molecule inhibitors and alternative modalities targeting PLKs, ongoing research and clinical trials are required to address challenges and unlock the full potential of this promising therapeutic approach. As research progresses and clinical data accumulate, the pharmaceutical industry is poised to capitalize on the therapeutic promise of PLK inhibition, shaping the future landscape of precision medicine and patient care.
Global PLK Targeted Therapies Market Opportunity & Clinical Trials Insight 2024 Report Highlights:
- PLK Targeted Therapies In Clinical Trials: > 10 Therapies
- USA Domination PLK Therapies Clinical Development Landscape: > 5 Therapies
- Breast Cancer Targeted Therapies In Clinical Trials: > 5 Therapies
- PLK Targeted Therapies Clinical Trials Insight By Company, Country, Indication & Phase
- Insight On Key Companies Involved In Development Of PLK Therapies
- PLK Targeted Therapy Combination Strategies With Chemotherapies, Immunotherapies & Targeted Therapies
PLKs regulate several stages of the cell cycle, including mitosis, centrosome maturation, spindle assembly, chromosomal segregation, and cytokinesis. They also take part in DNA damage response and checkpoint control systems. Overexpression and dysregulation of PLKs have been observed in various types of cancer, contributing to uncontrolled cell proliferation, genomic instability, and resistance to chemotherapy and radiation therapy. Inhibition of PLKs can induce mitotic catastrophe, leading to cell cycle arrest and apoptosis in cancer cells.
Emerging evidence also suggests that PLKs may be involved in the regulating of immune cell function and inflammation, making them potential targets for autoimmune diseases such as lupus, rheumatoid arthritis, and multiple sclerosis. Further, some viruses, like human immunodeficiency virus (HIV) and hepatitis B virus (HBV), hijack host PLKs for their replication and pathogenesis, suggesting that PLK targeted therapies m ay have antiviral effects by dampening these processes.
As a result of these growing investigations, various small molecule inhibitors of PLKs have been found and are being developed, with some currently in clinical trials. Onvansertib, a PLK1 inhibitor developed by Cardiff Oncology, is currently the most advanced candidate in clinical trials. Onvansertib is being studied in a phase 2 trial to determine its safety and efficacy in patients with small cell lung cancer (SCLC) who have not responded to or are unable to tolerate chemotherapy. Aside from being researched in several solid malignancies, Onvansertib is currently undergoing a phase 1 trial to determine its efficacy and safety in the treatment of patients with recurrent or refractory chronic myelomonocytic leukemia.
Other candidates in the pipeline include RP-1664 and BAL0891, which are being assessed in solid cancers and CFI-400945, being studied for various hematological cancers. The progression of these candidates through the pipeline reflects the growing interest and confidence in PLK targeted therapies.
In addition to small molecule inhibitors, antisense oligonucleotides and PROTACs (proteolysis-targeting chimeras) are being investigated as potential PLK targets. Antisense oligonucleotides can selectively reduce PLK mRNA expression, whereas PROTACs cause proteasomal breakdown of PLK proteins, providing alternative methods to conventional kinase inhibitors. While these methods have shown promise in research and preclinical trials, their clinical implementation has proven difficult for a variety of reasons. However, ongoing research seeks to create more selective and powerful alternatives with better safety profiles.
As interest in PLK targeted therapies grows, pharmaceutical companies will have an opportunity to create and commercialize innovative PLK inhibitors or other PLK-targeting modalities. PLK inhibitors, degraders, and silencers have the potential to meet unmet medical needs in cancer, autoimmune disorders, and viral diseases, making them a valuable market opportunity. Established pharmaceutical corporations may seek alliances and partnerships with academic institutions or biotech companies to work on PLK targeted therapies, leveraging their experience and accelerating the development of novel treatments.
Looking ahead, the future of PLK targeted therapies in the pharmaceutical sector is promising. Continued research efforts, novel drug discovery techniques, and clinical advances will propel the development of next-generation PLK targeted therapies with enhanced efficacy and safety profiles. PLK inhibitors may be used in combination with other anticancer treatments to improve therapeutic efficacy and overcome resistance mechanisms. Furthermore, as our understanding of the genetic and molecular profiles of various cancers and disorders grows, PLK-targeted therapies may be customized to specific patient populations using biomarkers or genetic fingerprints.
In conclusion, PLK targeted therapies are a rapidly developing field with revolutionary promise across a wide range of disease areas. While significant progress has been made in the development of small molecule inhibitors and alternative modalities targeting PLKs, ongoing research and clinical trials are required to address challenges and unlock the full potential of this promising therapeutic approach. As research progresses and clinical data accumulate, the pharmaceutical industry is poised to capitalize on the therapeutic promise of PLK inhibition, shaping the future landscape of precision medicine and patient care.
1. RESEARCH METHODOLOGY
2. INTRODUCTION TO PLK TARGETED THERAPY
2.1 Overview
2.2 Development & Evolution
3. PLK TARGETED THERAPY CLINICAL APPROACHES
3.1 Small Molecule Inhibitors
3.2 RNA Interference
3.3 Antisense Oligonucleotides
3.4 PROTAC Degraders
4. PLK TARGETED THERAPY CLINICAL APPLICATION BY INDICATION
4.1 Cancer
4.1.1 Overview
4.1.2 Ongoing Research & Development
4.2 Microbial Infections
4.3 Autoimmune Diseases
5. PLK TARGETED THERAPY COMBINATION STRATEGIES
5.1 Combination with Chemotherapies
5.2 Combination with Immunotherapies
5.3 Combination with Targeted Therapies
6. PLK TARGETED THERAPIES MARKET OVERVIEW
6.1 Current Market Trends
6.2 Future Commercialization Outlook
7. PLK TARGETED THERAPIES MARKET DYNAMICS
7.1 Market Drivers & Opportunities
7.2 Market Challenges & Restraints
8. GLOBAL PLK TARGETED THERAPIES CLINICAL TRIALS OVERVIEW
8.1 By Phase
8.2 By Country
8.3 By Company
8.4 By Indication
8.5 By Priority Status
8.6 Patient Segment
9. PLK TARGETED THERAPIES CLINICAL TRIALS INSIGHT BY COMPANY, COUNTRY & INDICATION
9.1 Research
9.2 Preclinical
9.3 Phase I
9.4 Phase I/II
9.5 Phase II
9.6 Phase III
10. COMPETITIVE LANDSCAPE
10.1 Biogenera
10.2 Boehringer Ingelheim
10.3 Cardiff Oncology
10.4 Cyclacel Pharmaceutical
10.5 Korea United Pharm
10.6 ORIC Pharmaceuticals
10.7 Pdx Pharmaceuticals
10.8 Repare Therapeutics
10.9 SillaJen Biotherapeutics
10.10 Treadwell Therapeutics
Figure 2-1: Some Biological Functions of PLKs
Figure 2-2: PLK-Targeted Therapies - Chronology of Events
Figure 4-1: Rigosertib Early Phase 1 (NCT04177498) Study – Initiation & Completion Year
Figure 4-2: Rigosertib Phase 1/2a (NCT04263090) Study – Initiation & Completion Year
Figure 4-3: Rigosertib Phase 2 (NCT05764395) Study – Initiation & Completion Year
Figure 4-4: Onvansertib Phase 2 (NCT06106308) Study – Initiation & Completion Year
Figure 4-5: Onvansertib Phase 2 (NCT05450965) Study – Initiation & Completion Year
Figure 4-6: Onvansertib Phase 1 (NCT05549661) Study – Initiation & Completion Year
Figure 4-7: Ocifisertib Phase 1/2 (NCT04730258) Study – Initiation & Completion Year
Figure 4-8: Ocifisertib Phase 2 (NCT03624543) Study – Initiation & Completion Year
Figure 4-9: Ocifisertib Phase 1 (NCT03187288) Study – Initiation & Completion Year
Figure 4-10: RP-1664 Phase 1 (NCT06232408) Study – Initiation & Completion Year
Figure 4-11: Plogosertib Phase 1 (NCT05358379) Study – Initiation & Completion Year
Figure 4-12: BAL0891 Phase 1 (NCT05768932) Study – Initiation & Completion Year
Figure 6-1: PLK Targeted Therapies – Future Opportunities
Figure 7-1: PLK Targeted Therapies Market - Drivers & Opportunities
Figure 7-2: PLK Targeted Therapies Market - Challenges & Restraints
Figure 8-1: Global – PLK Targeted Therapies Clinical Pipeline by Country (Numbers), 2024
Figure 8-2: Global – PLK Targeted Therapies Clinical Pipeline by Country (Numbers), 2024
Figure 8-3: PLK Targeted Therapies Clinical Pipeline by Company (Numbers), 2024
Figure 8-4: Global - PLK Targeted Therapies Clinical Pipeline by Indication (Numbers), 2024
Figure 8-5: Global - PLK Targeted Therapies Clinical Pipeline by Fast Track Designation (Numbers), 2024
Figure 8-6: Global - PLK Targeted Therapies Clinical Pipeline by Patient Segment (Numbers), 2024
Table 5-1: PLK Inhibitor & Chemotherapy Combinations in Clinical Trials, April’2024
2. INTRODUCTION TO PLK TARGETED THERAPY
2.1 Overview
2.2 Development & Evolution
3. PLK TARGETED THERAPY CLINICAL APPROACHES
3.1 Small Molecule Inhibitors
3.2 RNA Interference
3.3 Antisense Oligonucleotides
3.4 PROTAC Degraders
4. PLK TARGETED THERAPY CLINICAL APPLICATION BY INDICATION
4.1 Cancer
4.1.1 Overview
4.1.2 Ongoing Research & Development
4.2 Microbial Infections
4.3 Autoimmune Diseases
5. PLK TARGETED THERAPY COMBINATION STRATEGIES
5.1 Combination with Chemotherapies
5.2 Combination with Immunotherapies
5.3 Combination with Targeted Therapies
6. PLK TARGETED THERAPIES MARKET OVERVIEW
6.1 Current Market Trends
6.2 Future Commercialization Outlook
7. PLK TARGETED THERAPIES MARKET DYNAMICS
7.1 Market Drivers & Opportunities
7.2 Market Challenges & Restraints
8. GLOBAL PLK TARGETED THERAPIES CLINICAL TRIALS OVERVIEW
8.1 By Phase
8.2 By Country
8.3 By Company
8.4 By Indication
8.5 By Priority Status
8.6 Patient Segment
9. PLK TARGETED THERAPIES CLINICAL TRIALS INSIGHT BY COMPANY, COUNTRY & INDICATION
9.1 Research
9.2 Preclinical
9.3 Phase I
9.4 Phase I/II
9.5 Phase II
9.6 Phase III
10. COMPETITIVE LANDSCAPE
10.1 Biogenera
10.2 Boehringer Ingelheim
10.3 Cardiff Oncology
10.4 Cyclacel Pharmaceutical
10.5 Korea United Pharm
10.6 ORIC Pharmaceuticals
10.7 Pdx Pharmaceuticals
10.8 Repare Therapeutics
10.9 SillaJen Biotherapeutics
10.10 Treadwell Therapeutics
Figure 2-1: Some Biological Functions of PLKs
Figure 2-2: PLK-Targeted Therapies - Chronology of Events
Figure 4-1: Rigosertib Early Phase 1 (NCT04177498) Study – Initiation & Completion Year
Figure 4-2: Rigosertib Phase 1/2a (NCT04263090) Study – Initiation & Completion Year
Figure 4-3: Rigosertib Phase 2 (NCT05764395) Study – Initiation & Completion Year
Figure 4-4: Onvansertib Phase 2 (NCT06106308) Study – Initiation & Completion Year
Figure 4-5: Onvansertib Phase 2 (NCT05450965) Study – Initiation & Completion Year
Figure 4-6: Onvansertib Phase 1 (NCT05549661) Study – Initiation & Completion Year
Figure 4-7: Ocifisertib Phase 1/2 (NCT04730258) Study – Initiation & Completion Year
Figure 4-8: Ocifisertib Phase 2 (NCT03624543) Study – Initiation & Completion Year
Figure 4-9: Ocifisertib Phase 1 (NCT03187288) Study – Initiation & Completion Year
Figure 4-10: RP-1664 Phase 1 (NCT06232408) Study – Initiation & Completion Year
Figure 4-11: Plogosertib Phase 1 (NCT05358379) Study – Initiation & Completion Year
Figure 4-12: BAL0891 Phase 1 (NCT05768932) Study – Initiation & Completion Year
Figure 6-1: PLK Targeted Therapies – Future Opportunities
Figure 7-1: PLK Targeted Therapies Market - Drivers & Opportunities
Figure 7-2: PLK Targeted Therapies Market - Challenges & Restraints
Figure 8-1: Global – PLK Targeted Therapies Clinical Pipeline by Country (Numbers), 2024
Figure 8-2: Global – PLK Targeted Therapies Clinical Pipeline by Country (Numbers), 2024
Figure 8-3: PLK Targeted Therapies Clinical Pipeline by Company (Numbers), 2024
Figure 8-4: Global - PLK Targeted Therapies Clinical Pipeline by Indication (Numbers), 2024
Figure 8-5: Global - PLK Targeted Therapies Clinical Pipeline by Fast Track Designation (Numbers), 2024
Figure 8-6: Global - PLK Targeted Therapies Clinical Pipeline by Patient Segment (Numbers), 2024
Table 5-1: PLK Inhibitor & Chemotherapy Combinations in Clinical Trials, April’2024
